Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases

MLA

Cairoli R, et al. “Imatinib Mesylate in the Treatment of Core Binding Factor Leukemias with KIT Mutations. A Report of Three Cases.” Leukemia Research, vol. 29, no. 4, July 2004. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid.dedup....80fdc502543b827909185c671c61de0d&authtype=sso&custid=ns315887.

APA

Cairoli R, Beghini A, Morello E, Grillo G, Montillo M, Larizza L, & Morra E. (2004). Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases. Leukemia Research, 29(4).

Chicago

Cairoli R, Beghini A, Morello E, Grillo G, Montillo M, Larizza L, and Morra E. 2004. “Imatinib Mesylate in the Treatment of Core Binding Factor Leukemias with KIT Mutations. A Report of Three Cases.” Leukemia Research 29 (4). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid.dedup....80fdc502543b827909185c671c61de0d&authtype=sso&custid=ns315887.